Gilead Sciences completes $7.8 billion Arcellx acquisition Apr 28, 2026 08:45AM
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel Apr 28, 2026 08:45AM
Kite (GILD) and Arcellx (ACLX) Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program May 9, 2024 04:08PM
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program May 9, 2024 04:05PM
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program May 9, 2024 04:05PM


May 9, 2024 04:00PM Arcellx Provides First Quarter 2024 Financial Results
May 7, 2024 04:00PM Arcellx to Participate in Two Upcoming Investor Conferences
Apr 4, 2024 04:00PM Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Mar 20, 2024 04:00PM Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Feb 29, 2024 04:00PM Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
Feb 28, 2024 04:00PM Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
Dec 8, 2023 04:02PM Arcellx (ACLX) Announces Long-Term Responses from CART-ddBCMA Phase 1 Expansion Trial in Patients with R/R Multiple Myeloma at ASH
Dec 8, 2023 04:00PM Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
Nov 15, 2023 06:00AM Kite (GILD) and Arcellx (ACLX) Expand Strategic Partnership
Nov 15, 2023 06:00AM Kite and Arcellx Announce Expansion in Strategic Partnership
Nov 15, 2023 06:00AM ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
Nov 13, 2023 04:00PM Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights
Nov 2, 2023 09:00AM Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition
Oct 26, 2023 04:00PM Arcellx to Participate in Two Upcoming Investor Conferences
Aug 14, 2023 04:00PM Arcellx (ACLX) Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program; Reports Q2
Aug 14, 2023 04:00PM Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results
May 8, 2023 04:00PM Arcellx Provides First Quarter Financial Results
Apr 13, 2023 04:01PM Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
Mar 29, 2023 04:03PM Arcellx (ACLX) Reports Q4, Provides Business Highlights
Mar 29, 2023 04:01PM Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
Feb 21, 2023 04:00PM Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference
Feb 2, 2023 04:00PM Arcellx to Participate in Upcoming Investor Conferences
Jan 30, 2023 09:00AM Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Dec 9, 2022 08:17AM Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Dec 9, 2022 08:16AM Arcellx (ACLX) and Kite (GILD) Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
Dec 9, 2022 08:15AM Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma